Cargando…
Optimal dosage of cefmetazole for intraoperative antimicrobial prophylaxis in patients undergoing surgery for colorectal cancer
BACKGROUND: Few studies have reported the dosage of cefmetazole (CMZ) for intraoperative antimicrobial prophylaxis in patients underwent surgery for colorectal cancer. We therefore examined the optimal intraoperative dosage of CMZ according to pharmacokinetic/pharmacodynamic (PK/PD) theory in patien...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5219696/ https://www.ncbi.nlm.nih.gov/pubmed/28074152 http://dx.doi.org/10.1186/s40780-016-0071-6 |
_version_ | 1782492504085495808 |
---|---|
author | Tomizawa, Atsushi Nakamura, Takatoshi Komatsu, Toshiaki Inano, Hiroshi Kondo, Rumiko Watanabe, Masahiko Atsuda, Koichiro |
author_facet | Tomizawa, Atsushi Nakamura, Takatoshi Komatsu, Toshiaki Inano, Hiroshi Kondo, Rumiko Watanabe, Masahiko Atsuda, Koichiro |
author_sort | Tomizawa, Atsushi |
collection | PubMed |
description | BACKGROUND: Few studies have reported the dosage of cefmetazole (CMZ) for intraoperative antimicrobial prophylaxis in patients underwent surgery for colorectal cancer. We therefore examined the optimal intraoperative dosage of CMZ according to pharmacokinetic/pharmacodynamic (PK/PD) theory in patients who undergoing surgery for colorectal cancer. METHODS: The study group comprised 23 patients with colorectal cancer who underwent surgery, using CMZ as antimicrobial treatment to prevent postoperative infection. CMZ was administered intravenously within 60 min before surgery. PK/PD analysis was performed by population pharmacokinetic analysis and Monte-Carlo simulation. RESULTS: The final population pharmacokinetic parameters of CMZ were as follows: CL(CMZ) = 0.0704 × creatinine clearance (Ccr) and Vd(CMZ) = 0.163 × body weight (Bw). In patients with a Ccr of ≥90 to <130 mL/min, the probability of achieving concentrations exceeding MIC was 52.9 to 82.2% at 2 h after the initial dose and less than 20% at 3 h after the initial dose. CONCLUSIONS: Additional doses of CMZ should be given every 2 h in patients with a Ccr of ≥90 to <130 mL/min, every 3 h in those with a Ccr of ≥50 to <90 mL/min, and every 4 to 5 h in those with a Ccr of ≥10 to <50 mL/min. |
format | Online Article Text |
id | pubmed-5219696 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-52196962017-01-10 Optimal dosage of cefmetazole for intraoperative antimicrobial prophylaxis in patients undergoing surgery for colorectal cancer Tomizawa, Atsushi Nakamura, Takatoshi Komatsu, Toshiaki Inano, Hiroshi Kondo, Rumiko Watanabe, Masahiko Atsuda, Koichiro J Pharm Health Care Sci Research Article BACKGROUND: Few studies have reported the dosage of cefmetazole (CMZ) for intraoperative antimicrobial prophylaxis in patients underwent surgery for colorectal cancer. We therefore examined the optimal intraoperative dosage of CMZ according to pharmacokinetic/pharmacodynamic (PK/PD) theory in patients who undergoing surgery for colorectal cancer. METHODS: The study group comprised 23 patients with colorectal cancer who underwent surgery, using CMZ as antimicrobial treatment to prevent postoperative infection. CMZ was administered intravenously within 60 min before surgery. PK/PD analysis was performed by population pharmacokinetic analysis and Monte-Carlo simulation. RESULTS: The final population pharmacokinetic parameters of CMZ were as follows: CL(CMZ) = 0.0704 × creatinine clearance (Ccr) and Vd(CMZ) = 0.163 × body weight (Bw). In patients with a Ccr of ≥90 to <130 mL/min, the probability of achieving concentrations exceeding MIC was 52.9 to 82.2% at 2 h after the initial dose and less than 20% at 3 h after the initial dose. CONCLUSIONS: Additional doses of CMZ should be given every 2 h in patients with a Ccr of ≥90 to <130 mL/min, every 3 h in those with a Ccr of ≥50 to <90 mL/min, and every 4 to 5 h in those with a Ccr of ≥10 to <50 mL/min. BioMed Central 2017-01-07 /pmc/articles/PMC5219696/ /pubmed/28074152 http://dx.doi.org/10.1186/s40780-016-0071-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Tomizawa, Atsushi Nakamura, Takatoshi Komatsu, Toshiaki Inano, Hiroshi Kondo, Rumiko Watanabe, Masahiko Atsuda, Koichiro Optimal dosage of cefmetazole for intraoperative antimicrobial prophylaxis in patients undergoing surgery for colorectal cancer |
title | Optimal dosage of cefmetazole for intraoperative antimicrobial prophylaxis in patients undergoing surgery for colorectal cancer |
title_full | Optimal dosage of cefmetazole for intraoperative antimicrobial prophylaxis in patients undergoing surgery for colorectal cancer |
title_fullStr | Optimal dosage of cefmetazole for intraoperative antimicrobial prophylaxis in patients undergoing surgery for colorectal cancer |
title_full_unstemmed | Optimal dosage of cefmetazole for intraoperative antimicrobial prophylaxis in patients undergoing surgery for colorectal cancer |
title_short | Optimal dosage of cefmetazole for intraoperative antimicrobial prophylaxis in patients undergoing surgery for colorectal cancer |
title_sort | optimal dosage of cefmetazole for intraoperative antimicrobial prophylaxis in patients undergoing surgery for colorectal cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5219696/ https://www.ncbi.nlm.nih.gov/pubmed/28074152 http://dx.doi.org/10.1186/s40780-016-0071-6 |
work_keys_str_mv | AT tomizawaatsushi optimaldosageofcefmetazoleforintraoperativeantimicrobialprophylaxisinpatientsundergoingsurgeryforcolorectalcancer AT nakamuratakatoshi optimaldosageofcefmetazoleforintraoperativeantimicrobialprophylaxisinpatientsundergoingsurgeryforcolorectalcancer AT komatsutoshiaki optimaldosageofcefmetazoleforintraoperativeantimicrobialprophylaxisinpatientsundergoingsurgeryforcolorectalcancer AT inanohiroshi optimaldosageofcefmetazoleforintraoperativeantimicrobialprophylaxisinpatientsundergoingsurgeryforcolorectalcancer AT kondorumiko optimaldosageofcefmetazoleforintraoperativeantimicrobialprophylaxisinpatientsundergoingsurgeryforcolorectalcancer AT watanabemasahiko optimaldosageofcefmetazoleforintraoperativeantimicrobialprophylaxisinpatientsundergoingsurgeryforcolorectalcancer AT atsudakoichiro optimaldosageofcefmetazoleforintraoperativeantimicrobialprophylaxisinpatientsundergoingsurgeryforcolorectalcancer |